Does having eosinophilic asthma treated with Fasenra make someone “high risk” for life insurance?
Life-insurance underwriting typically does not treat “eosinophilic asthma” as a blanket category. Instead, insurers look at how severe the disease is, how well it is controlled, and whether the person has had serious respiratory events (like hospitalizations, ER visits, or intubation). Eosinophilic asthma is often considered a higher-risk medical condition than uncomplicated asthma, but “high risk” status usually depends on the individual’s control and history rather than the fact that the person uses benralizumab (Fasenra).
Because Fasenra is a biologic used to control severe asthma and reduce exacerbations, some underwriting frameworks may view it as a sign that the person has active severe disease that required escalation of therapy—while others may see it as evidence of better control if exacerbations have stopped. The net risk assessment varies by insurer.
What underwriting details matter most for asthma on a policy application?
Insurers commonly focus on:
- Recent severity and control (symptoms, inhaler use, daily impact)
- Exacerbation history in the last 12–24 months (especially hospital/ER visits)
- Whether there have been near-fatal or life-threatening asthma events
- Lung function (often FEV1 or spirometry results, if available)
- Comorbidities (smoking history, obesity, sleep apnea, other lung disease, cardiac disease)
- Medication regimen and adherence (including whether a biologic like Fasenra is being used effectively)
Fasenra itself is usually not the decisive factor; the clinical record around asthma control is.
How does Fasenra use affect risk classification?
If Fasenra is prescribed for severe eosinophilic asthma, the insurer may consider that baseline severity required biologic-level treatment. However, outcomes matter. If the policyholder has had:
- Few or no exacerbations since starting Fasenra,
- No hospitalizations/urgent care for asthma,
- Stable symptoms and objective lung function,
underwriters may rate the applicant more favorably than someone with frequent attacks even if they are on advanced therapy.
Would insurers treat eosinophilic asthma as categorically uninsurable?
Generally, no. People with asthma can often obtain life insurance, including term life, though pricing and eligibility can range widely. The higher the history of severe exacerbations or complications, the more likely the policy will be offered at a higher premium, with substandard ratings, or with exclusions—depending on the insurer’s rules.
What can you do to improve eligibility or get a clearer answer?
If you’re applying, the most useful documents are those showing control:
- A letter from the treating clinician summarizing diagnosis (eosinophilic/severe asthma), severity, and control
- Dates and details of any exacerbations, ER visits, steroid bursts, or hospitalizations
- Spirometry/lung function tests
- A medication summary (including when Fasenra started and whether oral steroids are still needed)
If you want, share (1) age, (2) smoking status, (3) number of asthma exacerbations/hospitalizations in the last 2 years, and (4) whether you’re on oral steroids currently. I can explain what underwriting factors typically drive ratings and what questions an insurer will likely ask.
Important limits of this answer
Life insurance underwriting rules differ by country and by insurer, and they can change over time. Without the insurer and your specific medical timeline, it’s not possible to say definitively whether your case would be rated “high risk” versus rated normally with a small premium impact.
If you tell me your country and whether you’re asking about term life, whole life, or final expense, I can tailor the likely underwriting approach more closely.